Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Resulting from the merger of BioAlliance Pharma (France) and Topotarget (Denmark) in July 2014, Onxeo is a new leader in European biotechnology. Thanks to a unique portfolio of advanced stage products and dedicated teams of experts, Onxeo aims to take a leading position in the field of orphan oncology drugs. Through bringing pioneering drugs to market, the company wants to improve patients’ lives, fund continuous investment in R&D of orphan diseases, and create value for all company’s stakeholders and shareholders. It has three strategic programs in advanced development and two products already registered in the European and US markets, demonstrating its teams’ expertise and know-how.
49 boulevard du Général Martial Valin
75015 PARIS, France
Tel: +33 (0)1 45 58 76 00
Fax: +33 (0)1 45 58 08 81
Investors: investors@onxeo.com
Email: contact@onxeo.com
Website: www.onxeo.com
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Pouillot, VP of Life Sciences for TechnipFMC, introduces the business unit as a partner of choice in engineering and construction services for the industry. Pouillot goes on to explain…
CREAPHARM is a French company managing clinical supplies and providing CMO and distribution services for pharmaceuticals and cosmetics. Its CEO, Eric Placet, explains how he has reorganized the company to…
Asepta is medium-sized dermatology company based in Monaco with a 76-year history. Its CEO, Anne Marie Noir, shares the success stories the company has experienced in international markets, the challenges…
Philippe Chêne, president of Winncare, highlights the key developments of the group over the past three years – most notably its acquisition of the UK player Mangar Health. Chêne goes…
Christine Placet, CEO of French biotech Horama, discusses the objective of becoming one of the key players in the field of ophthalmic gene therapy. She explains how Horama’s unique pipeline…
Thomas Clozel, co-founder and CEO of OWKIN, elaborates on how AI can be applied to the pharmaceutical industry to revolutionize today’s drug discovery and development process. He also comments on…
André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses…
Bertrand L’Huillier, president of Smith & Nephew France, highlights how the medtech firm is able to understand the objectives and needs of hospitals better with a B2B approach. He also…
Claude Le Pen, a prominent healthcare economist and consultant for IQVIA, shares his view on the state of French and European social dynamics today and outlines the key trends shaping…
François Vorms, managing director of Canon Medical Systems France, shares the story of how the company navigated its transition from Toshiba to become a well-known player in the medical imaging…
Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the…
Eric Le Roy, director general of SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The French National Association of the Medical Technologies Industry) discusses the profile of French medtech today,…
See our Cookie Privacy Policy Here
